Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IN8BIO, INC. Director's Dealing 2024

Oct 8, 2024

35200_dirs_2024-10-08_9551b85e-ea2e-4278-b029-a0d42b34adcc.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IN8BIO, INC. (INAB)
CIK: 0001740279
Period of Report: 2024-10-04

Reporting Person: Ho William Tai-Wei (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-10-04 Common Stock A 126582 Acquired 2548094 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-10-04 Series A Warrants (right to buy) $1.25 D 81967 Disposed 2025-06-13 Common Stock (81967) Direct
2024-10-04 Series A Warrants (right to buy) $0.45 A 81967 Acquired 2025-10-04 Common Stock (81967) Direct
2024-10-04 Series C Warrants (right to buy) $0.27 A 126582 Acquired 2027-10-04 Common Stock (126582) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 72999 Indirect
Common Stock 73000 Indirect
Common Stock 36500 Indirect
Common Stock 36500 Indirect
Common Stock 36500 Indirect

Footnotes

F1: The reported securities are included within 126,582 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share of common stock and one Series C warrant representing the right to purchase 126,582 shares of common stock.

F2: The shares are held by a relative of the Reporting Person. The Reporting Person has voting power pursuant to a voting proxy.

F3: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025.

F4: Fully vested and exercisable.

F5: The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.